Delivery Order SPE2DB22D9311-SPE2DB25FP6YT

Award Date 5/12/25
Potential Completion Date 5/13/25
Potential Value $6.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $17,022.00 firm fixed-price delivery order is for the supply of 4568292980 BOOSTRIX TDAP VACCINE SYRINGE 0.5ML, with a period of performance through May 14, 2025. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order valued at $1,136.56 for the BOOSTRIX TDAP VACCINE SYRINGE 0.5ML. It is a firm fixed-price contract with an ultimate completion date of April 14, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $7,387.64, is for the delivery of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML. The contract has a performance period through April 28, 2025 and is a firm fixed-price delivery order. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $6,815.90 firm fixed-price contract is for the procurement of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML, a pharmaceutical product, with a period of performance ending on January 17, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, enabling the...
The federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,880.40 firm fixed-price delivery order is for the supply of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML to fulfill the recurring medical supply needs of military health facilities. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Boostrix TDAP vaccine syringes, with a ceiling value of $3,409.68 and a completion date of February 7, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $28,076.00, is a firm fixed-price delivery order for BOOSTRIX TDAP VACCINE SYRINGE 0.5ML. The award is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,059.42 contract is for the supply of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML to support the medical supply needs of military health facilities. DMS Pharmaceutical Group has a significant single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 with the DLA under the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,807.60 firm fixed-price contract is for the supply of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue...
This is a $28,696.68 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the BOOSTRIX TDAP vaccine syringe, 0.5 mL, with a completion date of June 14, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders...
  • SPE2DB22D9311
    Indefinite Delivery Contract
  • SPE2DB22D9311-SPE2DB25FP6YT
    Delivery Order

This federal contract award is for the delivery of BOOSTRIX TDAP VACCINE SYRINGE 0.5ML to the Defense Logistics Agency (DLA). The $6,535.22 firm fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has an ultimate completion date of May 13, 2025.

DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables.

Generated 8/17/25, 1:08 AM